Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe - A Hungarian nationwide observational study

BMC Gastroenterology

Volumn 9, Issue , 2009, Pages 66-

  Miheller, Pál ^a   Lakatos, Péter L ^a   Horváth, Gábor ^b   Molnár, Tamás ^c   Szamosi, Tamás ^d   Czeglédi, Zsófia ^d   Salamon, Ágnes ^e   Czimmer, József ^f   Rumi, György ^f   Palatka, Károly ^g   Papp, Mária ^g   Jakab, Zsolt ^h   Szabó, Andrea ⁱ   Gelley, András ^j   Lakatos, László ^k   Barta, Zsolt ^g   Balázs, Csaba ^j   Rácz, István ⁱ   Zeher, Margit ^b   Döbrönte, Zoltán ^h   Altorjay, István ^g   Hunyady, Béla ^f   Simon, László ^e   Papp, János ^a   Banai, János ^d   Nagy, Ferenc ^c   Lonovics, János ^c   Újszászy, László ^b   Muzes, Györgyi ^a   Herszényi, László ^a   Tulassay, Zsolt ^a   more..

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Semmelweis Hospital   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

^d NATIONAL MEDICAL CENTER   (Hungary)

^e Balassa Janos Hospital   (Hungary)

^f UNIVERSITY OF PÉCS   (Hungary)

^g UNIVERSITY OF DEBRECEN   (Hungary)

^h Markusovszky Teaching Hospital   (Hungary)

ⁱ Petz Aladár Hospital   (Hungary)

^j Department of Medicine Csolnoky Ferenc Hospital ^*  (Hungary)

^k NONE   (Hungary)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INFLIXIMAB; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ABDOMINAL SURGERY; ADULT; ARTICLE; CROHN DISEASE; DATA ANALYSIS; DELAYED HYPERSENSITIVITY; DEMOGRAPHY; DISEASE DURATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EUROPE; FEMALE; HEALTH CARE FACILITY; HUMAN; HUNGARY; INFECTION; INTESTINE FISTULA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; OBSERVATIONAL STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; HUMANS; HUNGARY; HYPERSENSITIVITY; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 70449347809     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-9-66     Document Type: Article

References (21)

1. Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, Peppercorn MA. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000, 95(12):3490-3497. 10.1111/j.1572-0241.2000.03366.x, 11151882.
2. Hommes DW, Heisteeg BH, Spek M, Bartelsman JF, van Deventer SJ. Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital. Inflamm Bowel Dis 2002, 8(2):81-86. 10.1097/00054725-200203000-00002, 11854604.
3. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005, 128(4):862-869. 10.1053/j.gastro.2005.01.048, 15825070.
4. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353(23):2462-2476. 10.1056/NEJMoa050516, 16339095.
5. Cohen RD. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm Bowel Dis 2001, 7(Suppl 1):S17-22. 10.1002/ibd.3780070505, 11380038.
6. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, G VANA, Hoffman I, Van Steen K, Vermeire S, Rutgeerts PJ. Long-term outcome of treatment with infliximab in 614 Crohn's disease patients: results from a single centre cohort. Gut 2009, 58(4):492-500. 10.1136/gut.2008.155812, 18832518.
7. Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002, 97(9):2357-2363. 10.1111/j.1572-0241.2002.05991.x, 12358256.
8. Orlando A, Colombo E, Kohn A, Biancone L, Rizzello F, Viscido A, Sostegni R, Benazzato L, Castiglione F, Papi C, Meucci G, Riegler G, Mocciaro F, Cassinotti A, Cosintino R, Geremia A, Morselli C, Angelucci E, Lavagna A, Rispo A, Bossa F, Scimeca D, Cottone M. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig Liver Dis 2005, 37(8):577-583. 10.1016/j.dld.2005.01.019, 15886081.
9. Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. Dig Liver Dis 2005, 37(6):407-417. 10.1016/j.dld.2004.12.013, 15893279.
10. Feagan BGMJ, Ponich T. A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn's disease. Gastroenterology 2008, 135(1):294-295.
11. Colombel JFRP, Reinisch W, Mantzaris GJ, Rachmilewitz D, Lichtiger S, D'Haens G, Woude CJ, Diamond RH, Broussard D, Hegedus R, Sandborn WJ. SONIC: A randomized, double-blind, controlled trial comparing infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gut 2008, 57(Suppl II). OP001(abstract).
12. Rispo A, Lembo G, Insabato L, Cozzolino A, Pesce G, Castiglione F. Successful treatment of therapy-resistant metastatic Crohn's disease with infliximab. Br J Dermatol 2004, 150(5):1045-1046. 10.1111/j.1365-2133.2004.05958.x, 15149534.
13. Molnár TFK, Miheller P, Nyári T, Szepes Z, Herszényi L, Müzes G, Nagy F, Tulassay Z, Wittmann T. Is the efficacy of successful infliximab induction therapy maintained for one year lasting without retreatment in different behavior types of Crohn's disease. Journal of Crohn's and Colitis 2008, 2(4):322-326.
14. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol 2002, 97(12):2962-2972. 10.1111/j.1572-0241.2002.07093.x, 12492177.
15. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003, 124(4):917-924. 10.1053/gast.2003.50145, 12671888.
16. Duburque C, Lelong J, Iacob R, Seddik M, Desreumaux P, Fournier C, Wallaert B, Cortot A, Colombel JF. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. Aliment Pharmacol Ther 2006, 24(5):851-858. 10.1111/j.1365-2036.2006.03026.x, 16918890.
17. Hanauer SRP, Targan S, Kam L, Present D, Mayer L, Wagner C, LaSorda J, Sands B, Livingston R. Delayed hypersensitivity to infliximab (Remicade) re-infusion after a 2-4 year interval without treatment (abstract). Gastroenterology 1999, 116. A731(abstract).
18. Miheller P, Muzes G, Lakatos G, Mihaly E, Tulassay Z. Repeated infliximab therapy after serum sickness-like reaction in Crohn's disease. J Emerg Med 2007, 32(2):209-210. 10.1016/j.jemermed.2006.12.005, 17307639.
19. Jonas JBF, Kiss P, Peterfine TM. Incidence and prevalence of tuberculosis in Hungary in 2005. , http://www.koranyi.hu/evkonyv05/incidencia.htm
20. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006, 4(5):621-630. 10.1016/j.cgh.2006.03.002, 16678077.
21. JF Colombel GDH, Rutgeerts P, Panes J, Fleig WE, Prantera C, Bokemeyer B, Barai U, Wiekowski M. No new safety signals identified in Crohn's disease patients treated with infliximab in an interim review of the ENCORE registry. Journal of Crohn's and Colitis 2009, 2(1). P013(abstract).